Status: Recruiting
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.
Participants needed: 96
Trial details
Phase: Phase 2Age: 20+Biological sex: AllType: InterventionalSponsor: Blue Blood Biotech Corp.Updated: Apr 22, 2026Locations: 5
Eligibility criteria
Male or female, at least 20 years of age (inclusive) at the date of Screening [+9]
Clinical signs and symptoms of infection of target ulcer assessed by clinical ev... [+27]